SCHEMBL338644

SCHEMBL338644

CCCCCCCCCC#C[C]=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 7/20 0.55
PTPN7 P35236 5/20 0.55
SELP P16109 1/20 0.49
RECQL P46063 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
MCL1 Q07820 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 1/20 0.40
THRB P10828 1/20 0.40
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5845029 1.00 HMGCR (0.55) HMGCRPTPN7SELPRECQLTDP1
SCHEMBL2395804 1.00 HMGCR (0.55) HMGCRPTPN7SELPRECQLTDP1
SCHEMBL4148858 1.00 HMGCR (0.55) HMGCRPTPN7SELPRECQLTDP1
SCHEMBL5845890 1.00 HMGCR (0.55) HMGCRPTPN7SELPRECQLTDP1
SCHEMBL5845203 1.00 HMGCR (0.55) HMGCRPTPN7SELPRECQLTDP1
SCHEMBL4130261 1.00 HMGCR (0.55) HMGCRPTPN7SELPRECQLTDP1
SCHEMBL2393399 0.97
SCHEMBL6408336 0.91 HMGCR (0.57) HMGCRPTPN7SELPRECQLTDP1
SCHEMBL10777606 0.91 HMGCR (0.57) HMGCRPTPN7SELPRECQLTDP1
SCHEMBL953771 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050119181-A1 Hydrophobically-modified protein compositions and methods BIOGEN IDEC INC. (US) 2005-06-02 US claimed
EP-1036092-B1 Hydrophobically-modified hedgehog protein compositions and methods BIOGEN INC (US) 2005-05-11 EP claimed
EP-1036092-A2 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN, INC. (US) 2000-09-20 EP claimed
WO-1999028343-A9 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN INC (US) 1999-10-14 WO claimed
WO-1999028343-A2 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN, INC. (US) 1999-06-10 WO claimed
US-9321992-B2 Cell targeting methods and compositions CASE WESTERN RESERVE UNIVERSITY (US) 2016-04-26 US disclosed
US-20150313945-A1 COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY BOWEL DISEASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed
US-8932852-B2 Compositions and methods of treating inflammatory bowel disease CASE WESTERN RESERVE UNIVERSITY (US) 2015-01-13 US disclosed
US-8906279-B2 Manufacturing method of polarizing plate protective film, polarizing plate protective film, polarizing plate, and liquid crystal display device KONICA MINOLTA OPTO, INC. (JP) 2014-12-09 US disclosed
EP-1646395-B1 METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY CURIS INC (US) 2014-11-05 EP disclosed
US-8669346-B2 Bone marrow targeting peptides CASE WESTERN RESERVE UNIVERSITY (US) 2014-03-11 US disclosed
US-20130085096-A1 REGULATION OF LUNG TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-04-04 US disclosed
WO-2000015246-A2 REGULATION OF LUNG TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2000-03-23 WO disclosed
WO-1999028343-A9 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN INC (US) 1999-10-14 WO disclosed
WO-1999028343-A2 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN, INC. (US) 1999-06-10 WO disclosed
WO-1999020298-A1 REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO ONTOGENY, INC. (US) 1999-04-29 WO disclosed
WO-1999010004-A2 REGULATION OF MUSCLE TISSUES BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO ONTOGENY, INC. (US) 1999-03-04 WO disclosed
US-5801274-A N- mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 1998-09-01 US disclosed
US-5591891-A PEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1997-01-07 US disclosed
WO-1994017036-A1 S-LIPOPHILIC ALIPHATIC CARBONYL [N-MERCAPTOACYL-(AMINO ACID OR PEPTIDE)] COMPOUNDS AS ANTIHYPERTENSIVE AGENTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1994-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085096-A1 REGULATION OF LUNG TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO SHH, FGF1, HGF HMGCR 3940/4885PTPN7 742/4885SELP 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.